How will personalized medicine change business models?
Personalized medicine holds the potential to deliver many benefits for patients and other parties in the healthcare system, but it also has the potential to radically alter business models.
I have asked the question “Will personalized medicine be a driver for widespread price controls?” and a new analysis from Booz & Company dives even deeper and A Strategist’s Guide to Personalized Medicine.
What are your thoughts on the extra-patient/payer benefits that personalized medicine will bring, and how the biopharma industry should adjust? Sound off in the comments below.